Key Takeaways
- Puma Biotechnology reported a fourth-quarter net income of $13.4 million for 2025, down from $19.3 million in 2024.
- Product revenue for the fourth quarter increased to $59.9 million, while total revenue was $75.5 million.
- Debt was reduced to $22.5 million, with net operating cash flow rising to $41.8 million in 2025.
Financial Overview
Puma Biotechnology, Inc. has announced its financial results for the fourth quarter and full year ending December 31, 2025, showcasing ongoing profitability and operational advancements, primarily driven by the commercial success of its product, NERLYNX®.
In the fourth quarter of 2025, the company reported a net income of $13.4 million, or $0.27 per basic share and $0.26 per diluted share. This reflects a decrease compared to $19.3 million, or $0.39 per share, in the same period of 2024. However, the overall net income for the full year reached $31.1 million, slightly up from $30.3 million in 2024.
Product revenue for the fourth quarter increased to $59.9 million from $54.4 million in 2024. For the entire year, net product revenue rose to $204.1 million, compared to $195.2 million in 2024. The total revenue for Q4 2025 was $75.5 million, including $15.6 million in royalties, a notable increase from $59.1 million in Q4 2024. However, total annual revenue decreased to $228.4 million from $230.5 million the previous year.
Operational Highlights
Sales of NERLYNX® remain the sole driver of Puma’s product revenue. The company successfully reduced its total operating costs for 2025 to $191.1 million, down from $199.5 million in 2024. This reduction resulted mainly from a $9.4 million decrease in selling, general, and administrative expenses, attributable to fewer legal fees linked to litigation with AstraZeneca in 2024.
Debt Management and Future Outlook
Significant progress has been made in reducing total debt, which fell to $22.5 million by the close of 2025, down from $67.0 million at the end of 2024. Net cash from operating activities was reported at $41.8 million for the year, up from $38.9 million in 2024.
CEO Alan H. Auerbach lauded the company’s disciplined management practices, contributing to three consecutive years of profitability. Looking forward, Puma has provided guidance for 2026, anticipating first-quarter net product revenue between $36 million and $39 million, and full-year revenue between $194 million and $198 million. Net income for 2026 is expected to range from $10 million to $13 million.
The content above is a summary. For more details, see the source article.